Author(s): Prabhat Varshney, Prem Saini

Email(s): prabhatvarshney.pv@gmail.com , prem_hsaini@yahoo.co.in

DOI: 10.5958/0974-360X.2020.00529.6   

Address: Prabhat Varshney*, Prem Saini*
School of Pharmacy, Lingaya’s Vidyapeeth Faridabad, Haryana-121002, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 6,     Year - 2020


ABSTRACT:
Diroximel fumarate (DRF) is an oral disease-modifying agent indicated for the treatment of relapsing-remitting multiple sclerosis (RRMS), which is taken twice a day. In EVOLVE-MS-1, Phase 3, a two-year safety study evaluating DRF in patients with RRMS, it is shown that the occurrence of flushing and gastrointestinal treatment-emergent adverse events is comparatively low. This results in a low rate of discontinuation due to treatment-emergent adverse events as compared to dimethyl fumarate (DMF). Monomethyl fumarate (MMF) is a common active metabolite of DMF and DRF. This active metabolite is responsible for the mechanism of actions of the drugs since it crossed the blood-brain barrier. Methanol is the primary metabolite of DMF metabolism but a minor metabolite of DRF metabolism, which results in a lower risk of gastrointestinal symptoms. Both DMF and DRF show similar Tmax and Cmax, which indicate similarity in the efficacy of both the drugs. Therefore, DRF has a similar safety and efficacy profile but better tolerability of treatment-emergent adverse events when compared to DMF. This article provides an updated overview of the pharmacological, therapeutic efficacy, and tolerability of DRF.


Cite this article:
Prabhat Varshney, Prem Saini. An Overview of DRF in the treatment of Multiple Sclerosis. Research J. Pharm. and Tech 2020; 13(6): 2992-2996. doi: 10.5958/0974-360X.2020.00529.6

Cite(Electronic):
Prabhat Varshney, Prem Saini. An Overview of DRF in the treatment of Multiple Sclerosis. Research J. Pharm. and Tech 2020; 13(6): 2992-2996. doi: 10.5958/0974-360X.2020.00529.6   Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-82


REFERENCE:
1.    National Multiple Sclerosis Society. What is MS? 2015. http://www.nationalmssociety.org.
2.    The Effects of Multiple Sclerosis on Your Body https://www.healthline.com/health/multiple-sclerosis/effects-on-the-body#1.
3.    Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD011076. DOI: 10.1002/14651858.CD011076.pub2
4.    National Institute of Neurological Disorders and Stroke. Multiple sclerosis: hope through research.2015. http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm.  Accessed 07 NOV 2019
5.    Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. 2013;2013:708659
6.    Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545–55.
7.    Kim W, Zandona ME, Kim SH, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9–19.
8.    This Patient Information has been approved by the U.S. Food and Drug Administration      Revised: 10/2019 manufactured by r: Biogen Inc., Cambridge, MA 02142, www.VUMERITY.com
9.    Biogen. Tecfidera® (dimethyl fumarate) delayed- release capsules, for oral use. https://www.tecfidera.com/content/dam/commercial/multiple-sclerosis/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf. accessed 07 Nov 2019
10.    Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Investig. 2014;124(5):2188–92.
11.    European Medicines Agency. TECFIDERA summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2018/20180528141209/anx_141209_en.pdf. Accessed 07 Nov 2019.
12.    Fox EJ, Vasquez A, Grainger W, et al. Gastroin- testinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9–18.
13.    Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Phar- macol Sci. 2018;39(1):1–12.
14.    Centers for Disease Control and Prevention. Methanol: systemic agent U.S. Department of Health and Human Services. https://www.cdc.gov/ niosh/ershdb/emergencyresponsecard_29750029. html. Accessed 07 Nov 2019.
15.    Wehr A, Hard ML, Yu M, et al. Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects (P1.403). Neurology 2018; 90(Suppl. 15), https://n.neurology.org/content/90/15_ Supplement/P1.403
16.    Vumerity FDA label https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf. Accessed 09 Nov 2019
17.    Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH: Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004 Oct;58(4):429-32. doi: 10.1111/j.1365-2125.2004.02145.x. [PubMed:15373936]
18.    Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y: Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front Neurol. 2018 Jan 23;9:5. doi: 10.3389/fneur.2018.00005. eCollection 2018. [PubMed:29410647]
19.    Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, Miller C, Penner N: Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Adv Ther. 2019 Nov;36(11):3154-3165. doi: 10.1007/s12325-019-01085-3. Epub 2019 Sep 19. [PubMed:31538304]
20.    Moon CS. Estimations of the lethal and exposure doses for representative methanol symptoms in humans. Ann Occup Environ Med. 2017;29:44.
21.    Liesivuori J, Savolainen H. Methanol and formic acid toxicity: biochemical mechanisms. Pharmacol Toxicol. 1991;69(3):157–63.
22.    Kraut JA, Mullins ME. Toxic alcohols. N Engl J Med. 2018;378(3):270–80.
23.    The Human Protein Atlas. Alcohol dehydrogenases. https://www.proteinatlas.org/search/alcohol%252bdehydrogenase.  Accessed 10 Nov 2019.
24.    Haupt VJ, Daminelli S, Schroeder M. Drug promis- cuity in PDB: protein binding site similarity is key. PLoS One. 2013;8(6):e65894.
25.    Von Glehn F, Dias-Carneiro RPC, Moraes AS, et al. Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: implications for the treatment of multiple sclerosis. Mult Scler Relat Disord. 2018;23:46–50.
26.    Hosseini A, Masjedi A, Baradaran B, et al. Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis. J Cell Physiol. 2019;234(7):9943–55.
27.    Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2(4):421–9.
28.    Leong RW, Chan FK. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf. 2006;5(4):585–92.
29.    Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available